Home›Clinical trials›MAINTAIN (Mucosal AblatIoN Therapy After INcretins)

A study listed on ClinicalTrials.gov.

Recruiting now. Registry record last updated March 21, 2025.

Who can join
Adults 21 to 65, have obesity, BMI 30+.
What you take
Check ClinicalTrials.gov for this trial's study groups and what each group receives.
How long it lasts
The study runs about 17 months.
What you get
Costs vary by study. Ask the study team what this one covers, including the study medicine, visits and travel, before you sign the consent form.
This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.
Check my fit →
Phase Not ApplicableSponsor Dr. Christopher McGowanDrug investigational drugClass OtherSites 2 USEnrollment target 20

What this study is for

Primary condition: Obesity and Obesity-related Medical Conditions. Also studied in: Obesity and Overweight, Obesity Prevention, Obesity Recidivism, GLP-1, Ablation Techniques.

Full scientific study title: MAINTAIN (Mucosal AblatIoN Therapy After INcretins).

Who can join

Age21 to 65SexAnyBMI30 to 45

Adults 21 to 65, have obesity, BMI 30+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

  • Subjects aged 21-65
  • Body mass Index (BMI) ≥30 kilograms per square meter (kg/m²), or ≤45 kg/m²
  • Observed ≥ 10% TBWL with semaglutide or tirzepatide use for primary obesity therapy
  • Subject did not experience \>50% weight recurrence since discontinuation of semaglutide or tirzepatide
  • Maintained a stable dose of semaglutide or tirzepatide for a minimum of 12 weeks

Key exclusion criteria

  • Known diagnosis of type I or type II diabetes or a Hemoglobin A1c \> 6.5% at time of screening
  • Use of GLP-1 or GLP-1/GIP medication for the treatment of diabetes, rather than obesity.
  • Use of anticoagulation, antithrombotic agents, and/or NSAIDs that cannot be discontinued for a minimum of 12 weeks
  • Known bleeding diathesis that cannot be corrected through medical means.
  • History of decompensated end-organ disease

Where this trial is enrolling

This trial has 2 sites across 1 state. Contact a site coordinator directly to start screening.

North Carolina2 sites

Timeline

Started enrolling: January 1, 2025. Expected completion: June 2026. Last updated on ClinicalTrials.gov: March 21, 2025.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked September 4, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, editor of GLP Chart
John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this siteLinkedInContact
Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.